Supplemental data for the manuscript: Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial

Autor:	Powles, Thomas, Sridhar, Srikala S., Loriot, Yohann, Bellmunt, Joaquim, Jasmine Mu, Xinmeng, A. Ching, Keith, Pu, Jie, Sternberg, Cora N., Petrylak, Daniel P., Tambaro, Rosa, Dourthe, Louis M., ��lvarez-Fern��ndez, Carlos, Aarts, Maureen, Pietro, Alessandra di, Grivas, Petros, Davis, Craig B.
Rok vydání:	2021
Předmět:	110704 Cellular Immunology FOS: Clinical medicine Diseases 110702 Applied Immunology (incl. Antibody Engineering Xenotransplantation and T-cell Therapies) 111209 Solid Tumours 110105 Medical Biochemistry: Nucleic Acids 111505 Pharmacogenomics Health Care 111207 Molecular Targets 110706 Immunogenetics (incl. Genetic Immunology) 110707 Innate Immunity FOS: Medical biotechnology 110709 Tumour Immunology 111203 Cancer Genetics 111204 Cancer Therapy (excl. Chemotherapy and Radiation Therapy) Biomarkers
DOI:	10.25454/pfizer.figshare.14866920.v1
Popis:	These figures contain details of the study population, elastic net model parameters, and CytoPro method validation.These tables report results from statistical analyses of biomarker associations with overall survival in JAVELIN Bladder 100.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cecb6509dfe7167da2699dc8ddb8525 Zobrazit plný text záznamu